secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2023-05-15T23:59:59+00:00
Accession:  0001933414-23-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys Q1 net loss $12.6M from $7.6M YoY; cash $301.8M; Lorundrostat pivotal trial dosed
--------------------------------------------------------------------------------

- Net loss $12.6M vs $7.6M in Q1 2022; R&D expense $12.3M (up from $6.8M) driven by $4.0M milestone payment to Mitsubishi Tanabe.
- Cash, equivalents & investments $301.8M as of Mar 31, 2023, up from $110.1M; expected to fund operations through mid-2025.
- Initiated Advance-HTN Phase 2 pivotal trial (lorundrostat) in April 2023; topline data expected H1 2024.
- Plans to initiate Launch-HTN Phase 3 (H2 2023) and a CKD Phase 2 trial (mid-2023); Launch-HTN data expected mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/0001933414-23-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341423000035/mlys-20230515.htm
  HTML page:      https://secwatch.observer/filing/0001933414-23-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer